Table 1 Baseline characteristics of the study groups.
Variable | Preserflo | iStent | MD (95% CI) | p | ||
|---|---|---|---|---|---|---|
n (%)/Mean ± SD | Median (Q1;Q3) | n (%) / Mean ± SD | Median (Q1;Q3) | |||
N | 43 (100.0) | – | 78 (100.0) | – | – | – |
Sex, female | 30 (69.8) | – | 53 (67.9) | – | – | 0.9993 |
Age, years | 68.98 ± 10.09 | 70.00 (61.25; 75.00) | 72.48 ± 8.70 | 75.00 (67.00; 79.00) | − 3.50 (− 7.00; 0.00)1 | 0.0492 |
POAG | 34 (79.1) | – | 63 (80.8) | – | – | > 0.9993 |
PXG | 9 (20.9) | – | 15 (19.2) | – | ||
Medication number | 2.24 ± 1.32 | 2.00 (2.00; 3.00) | 1.79 ± 1.03 | 2.00 (1.00; 2.00) | 0.00 (0.00; 1.00) | 0.027 |
BCVA | 0.59 ± 0.33 | 0.60 (0.35; 1.00) | 0.56 ± 0.56 | 0.50 (0.34; 0.68) | 0.10 (− 0.03; 0.20) | 0.281 |
IOP, mmHg | 25.14 ± 6.53 | 23.00 (21.00; 28.00) | 21.94 ± 2.95 | 21.00 (20.00; 23.00) | 2.00 (1.00; 4.00) | 0.002 |